#United States #Clinical Research #Conshohocken #Wound Care #Tiger BioSciences

Major Advancements by Tiger BioSciences in 2025

In the realm of medical innovation, Tiger BioSciences has set a remarkable standard in 2025 by significantly expanding its investment in research and development. This proactive approach has led to commissioning several key clinical and scientific studies, establishing the company at the forefront of the wound care industry as it gears up for 2026.

Commitment to Evidence-Based Research

Tiger BioSciences has solidified its reputation by supporting five peer-reviewed clinical studies during the year, with particular attention to its flagship product, completeFT. Two of the studies shed light on the product's effectiveness in advanced wound management, affirming its trustworthiness among healthcare professionals nationwide. The focus on completeFT highlights not only the company's dedication to enhancing wound care outcomes but also its commitment to generating robust clinical validations.

Beyond retrospective studies, the company is also pioneering a prospective randomized controlled trial (RCT). This ongoing research evaluates caregraFT, another innovative product designed specifically for chronic wound care, such as diabetic foot ulcers and venous leg ulcers. Early findings from this trial show promising results, reinforcing caregraFT’s potential as a new standard for treating chronic wounds. Garrett Grinsfelder, President of Tiger Wound Care, emphasizes that verified clinical evidence is essential for sustainable innovation in the wound care sector.

Looking Forward

The momentum built in 2025 is set to continue as Tiger BioSciences plans to advance its clinical research program further. A new RCT is on the horizon, focusing on caregraFT's effectiveness in managing pressure ulcers. This ambitious undertaking reflects the company’s commitment to ensuring that their offerings are informed by rigorous research, providing health professionals and patients with solutions they can depend on.

Grinsfelder is optimistic about the future, stating, "With multiple peer-reviewed studies completed and two active RCTs scheduled for 2026, Tiger BioSciences stands out as a leader in the market, equipped with products driven by substantial scientific evidence.” The organization's proactive approach and dedication to patient care through extensive research investments reveal a promising path towards improved healthcare solutions.

About Tiger BioSciences

Tiger BioSciences serves as a vertically integrated cell and tissue technology enterprise focused on the recovery, processing, and distribution of cellular and matrix-like products. Functioning essentially as a tissue recovery agency and processing innovator, the company operates with a commitment to supporting clinicians while prioritizing patient and provider trust.

Through its significant investment in research for 2025, Tiger BioSciences not only aims to enhance its product portfolio but also endeavors to revolutionize the standard of care within the wound treatment arena, aiming for a brighter, more effective future in patient care.